Latest updates on chronic viral hepatitis B

Year 2016, , 33 - 37, 01.08.2016

Ramazan Idılman Fatih Karakaya

https://doi.org/10.5472/MMJsi.2901.07

Abstract

Hepatitis B virus (HBV) remains a major cause of liver-relatedmorbidity and mortality in Turkey and all over the world. Twodifferent types of antiviral agents can be used in the treatmentof chronic hepatitis B (CHB). Conventional (IFN) or pegylatedinterferon alpha (PegIFN), nucleoside [lamivudine (LMV),telbivudine, emtricitabine, entecavir (ETV)] and nucleotide analogs[adefovir dipivoxil (ADV)] and tenofovir disoproxil fumarate(TDF)]. Antiviral agent must ensure a degree of HBV viralsuppression and will lead to biochemical, serological remissionand histological improvement. Current treatment strategies arediscussed in present brief report.Keywords: Chronic hepatitis B, Nucleos(t)ide analog, Entecavir,Tenofovir disoproxil fumarate

References

• Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global
• epidemiology of hepatitis B virus infection: new estimates of
• age-specific HBsAg seroprevalence and endemicity. Vaccine
• 30:2212-19, doi: 10.1016.
• Tozun N, Ozdogan OC, Cakaloğlu Y, et al. Seroprevalence of
• hepatitis B and C virus infections and risk factors in Turkey
• a fieldwork TURHEP study, Clin Microbiol Infect. 2015
• Nov;21:1020-6. doi: 10.1016/j.cmi.2015.06.028.
• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology
• 45:507–39.
• EASL Clinical Practice Guidelines: Management of chronic
• hepatitis B virus infection. J Hepatol 2012;57: 167-85. doi
• 1016/j.jhep.2012.02.010.
• Lok A, McMahon B, Brown R, et al. Antiviral therapy for
• chronic hepatitis B virus infection in adults: a systematic
• review and meta-analysis. Hepatology 2015;63:284-306.
• doi: 10.1002/hep.28280
• Terrault NA, Bzowej NN, Kyong MS, Hwang JP, Jonas PP
• Murad MH. AASLD Guidelines for Treatment of Chronic
• Hepatitis B. Hepatology 2016;6:261-83. doi: 10.1002/
• hep.28156
• Chaung KT, Ha NB, Trinh HN, et al. High frequency of
• recurrent viremia after hepatitis B e antigen seroconversion
• and consolidation therapy. J Clin Gastroenterol 2012;46:865-
• doi: 10.1097/MCG.0b013e31825ceed9
• Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D
• Hadziyannis E. Sustained responses and loss of HBsAg in
• HBeAg-negative patients with chronic hepatitis B who
• stop long-term treatment with adefovir. Gastroenterology
• 143:629-36.e, doi: 10.1053/j.gastro.2012.05.039.
• Buster EH, Hansen BE, Buti M, Delwaide J, Niederau C
• Michielsen PP, et al. Peginterferon alpha-2b is safe and
• effective in HBeAg-positive chronic hepatitis B patients with
• advanced fibrosis. Hepatology 2007;46:388–94.
• Schiff E, Simsek H, Lee WM, et al. Efficacy and safety
• of entecavir in patients with chronic hepatitis B and
• advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol
• 103:2776–83. doi: 10.1111/j.1572-0241.2008.02086.
• Buti M, Hadziyannis S, Mathurin P, et al. Tenofovir
• disoproxil fumarate is highly active for treatment of chronic
• hepatitis B in subjects with cirrhosis. J Hepatol 2008;48:S33.
• Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir
• therapy results in the reversal of fibrosis/cirrhosis and
• continued histological improvement in patients with chronic
• hepatitis B. Hepatology 2010;52:886–93. doi: 10.1002/
• hep.23785.
• Idilman R, Gunsar F, Koruk M, et al. Long-term entecavir
• or tenefovir disoproxil fumarate therapy in treatment-naive
• chronic hepatitis B patients in the real-world setting. J Viral
• Hepatit 2015;22:504-10 doi:10.1111/jvh.12358.
• Papatheodoridis GV, Lampertico P, Manolakopoulos S
• Lok A. Incidence of hepatocellular carcinoma in chronic
• hepatitis B patients receiving nucleos(t)ide therapy: a
• systematic review. J Hepatol 2010;53:348–56, doi: 10.1016/j.
• jhep.2010.02.035.
• Cornberg M, Protzer U, Petersen J, et al. Prophylaxis
• diagnosis and therapy of hepatitis B virus infection – the
• German guideline. Z Gastroenterol 2011;49:871–930. doi
• 1055/s-0031-1273462.